{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:11:12Z","timestamp":1790388672344,"version":"4.1.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00627","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T11:26:07Z","timestamp":1590751567000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity"],"prefix":"10.3389","volume":"11","author":[{"given":"Joanne Marie M.","family":"Del Rosario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Risley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Temperton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othmar G.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon E.","family":"Hufton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet."},{"key":"B2","year":"2018","journal-title":"Influenza (Seasonal)."},{"key":"B3","year":"2018","journal-title":"Influenza (Avian and Other Zoonotic)."},{"key":"B4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMra1208802","article-title":"Pandemic preparedness and response\u2013lessons from the H1N1 influenza of 2009.","volume":"370","author":"Fineberg","year":"2014","journal-title":"N Engl J Med."},{"key":"B5","year":"2017","journal-title":"Key Facts about Seasonal Flu Vaccine."},{"key":"B6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJMp068030","article-title":"Antiviral resistance in influenza viruses \u2014 implications for management and pandemic response.","volume":"354","author":"Hayden","year":"2006","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med."},{"key":"B8","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection.","volume":"357","author":"Zhou","year":"2007","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1016\/j.vaccine.2016.08.057","article-title":"Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications.","volume":"34","author":"Sparrow","year":"2016","journal-title":"Vaccine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza a viruses.","volume":"16","author":"Sui","year":"2009","journal-title":"Nat Struct Mol Biol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.","volume":"3","author":"Throsby","year":"2008","journal-title":"PLoS One."},{"key":"B12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1080\/21645515.2017.1363135","article-title":"Antibody immunoprophylaxis and immunotherapy for influenza virus infection: utilization of monoclonal or polyclonal antibodies?","volume":"14","author":"Berry","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope.","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science."},{"key":"B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-095-9_1","article-title":"Viral vectors for gene therapy.","volume":"737","author":"Warnock","year":"2011","journal-title":"Methods Mol Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/B978-0-12-386509-0.00012-0","article-title":"Adeno-associated virus vectorology, manufacturing, and clinical applications.","volume":"507","author":"Grieger","year":"2012","journal-title":"Methods Enzymol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant adeno-associated viral integration and genotoxicity: insights from animal models.","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum Gene Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors.","volume":"21","author":"Daya","year":"2008","journal-title":"Clin Microbiol Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2015.07.006","article-title":"Adeno-associated virus serotypes for gene therapeutics.","volume":"24","author":"Lisowski","year":"2015","journal-title":"Curr Opin Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy.","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs."},{"key":"B20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nbt.2618","article-title":"Broad protection against influenza infection by vectored immunoprophylaxis in mice.","volume":"31","author":"Balazs","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-2-43","article-title":"Adeno-associated virus: from defective virus to effective vector.","volume":"2","author":"Goncalves","year":"2005","journal-title":"Virol J."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006299","article-title":"Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza.","volume":"5","author":"Limberis","year":"2013","journal-title":"Sci Transl Med."},{"key":"B23","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1128\/CVI.00545-13","article-title":"Vectored expression of the broadly neutralizing antibody FI6 in mouse airway provides partial protection against a new avian influenza A virus, H7N9.","volume":"20","author":"Limberis","year":"2013","journal-title":"Clin Vaccine Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1073\/pnas.0801367105","article-title":"Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies.","volume":"105","author":"Kashyap","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.celrep.2017.08.084","article-title":"Antibody 27F3 broadly targets influenza A group 1 and 2 hemagglutinins through a further variation in VH1-69 antibody orientation on the HA stem.","volume":"20","author":"Lang","year":"2017","journal-title":"Cell Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1039\/c0mb00310g","article-title":"Rare antibodies from combinatorial libraries suggests an S.O.S. component of the human immunological repertoire.","volume":"7","author":"Lerner","year":"2011","journal-title":"Mol Biosyst."},{"key":"B27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nri.2016.67","article-title":"Combinatorial antibody libraries: new advances, new immunological insights.","volume":"16","author":"Lerner","year":"2016","journal-title":"Nat Rev Immunol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103294","article-title":"The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.","volume":"9","author":"Hufton","year":"2014","journal-title":"PLoS One."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/antib8010014","article-title":"Cross-reactive and lineage-specific single domain antibodies against influenza B hemagglutinin.","volume":"8","author":"Ramage","year":"2019","journal-title":"Antibodies."},{"key":"B30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/protein\/7.9.1129","article-title":"Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains.","volume":"7","author":"Muyldermans","year":"1994","journal-title":"Protein Eng."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3201\/eid2506.181158","article-title":"Influenza D virus infection in dromedary camels, Ethiopia.","volume":"25","author":"Murakami","year":"2019","journal-title":"Emerg Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/antib8010001","article-title":"Single-domain antibodies and their formatting to combat viral infections.","volume":"8","author":"De Vlieger","year":"2018","journal-title":"Antibodies."},{"key":"B33","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.vetimm.2008.10.299","article-title":"Camelid immunoglobulins and nanobody technology.","volume":"128","author":"Muyldermans","year":"2009","journal-title":"Vet Immunol Immunopathol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.7150\/thno.17071","article-title":"Progress of small molecular inhibitors in the development of anti-influenza virus agents.","volume":"7","author":"Wu","year":"2017","journal-title":"Theranostics."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1074\/jbc.M307341200","article-title":"Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm.","volume":"279","author":"Stijlemans","year":"2004","journal-title":"J Biol Chem."},{"key":"B36","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/art.21827","article-title":"Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.","volume":"54","author":"Coppieters","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017665","article-title":"Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.","volume":"6","author":"Hultberg","year":"2011","journal-title":"PLoS One."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00315","article-title":"Antibody-based strategies to prevent and treat influenza.","volume":"6","author":"Shriver","year":"2015","journal-title":"Front Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura.","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164296","article-title":"Cross-neutralising nanobodies bind to a conserved pocket in the hemagglutinin stem region identified using yeast display and deep mutational scanning.","volume":"11","author":"Gaiotto","year":"2016","journal-title":"PLoS One."},{"key":"B41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/antib4030141","article-title":"Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended nanobodies (R).","volume":"4","author":"Hoefman","year":"2015","journal-title":"Antibodies."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody(R) ALX-0061 supports its clinical development in rheumatoid arthritis.","volume":"17","author":"Van Roy","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/srep30171","article-title":"Fusion of the mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus.","volume":"6","author":"Gunaydin","year":"2016","journal-title":"Sci Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jps.23783","article-title":"Pharmacokinetics of Peptide-Fc fusion proteins.","volume":"103","author":"Wu","year":"2014","journal-title":"J Pharm Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.","volume":"126","author":"DiLillo","year":"2016","journal-title":"J Clin Invest."},{"key":"B46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo.","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","article-title":"Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin.","volume":"362","author":"Laursen","year":"2018","journal-title":"Science."},{"key":"B48","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1517\/17425247.2014.871258","article-title":"The potential of adeno-associated viral vectors for gene delivery to muscle tissue.","volume":"11","author":"Wang","year":"2014","journal-title":"Expert Opin Drug Deliv."},{"key":"B49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nbt1073","article-title":"Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart.","volume":"23","author":"Wang","year":"2005","journal-title":"Nat Biotechnol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis.","volume":"481","author":"Balazs","year":"2011","journal-title":"Nature."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.1016\/j.vaccine.2016.10.053","article-title":"Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.","volume":"34","author":"Greig","year":"2016","journal-title":"Vaccine."},{"key":"B53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy.","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood."},{"key":"B54","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0014-5793(97)01062-4","article-title":"Selection and identification of single domain antibody fragments from camel heavy-chain antibodies.","volume":"414","author":"Arbabi Ghahroudi","year":"1997","journal-title":"FEBS Lett."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00161","article-title":"Pseudotype-based neutralization assays for influenza: a systematic analysis.","volume":"6","author":"Carnell","year":"2015","journal-title":"Front Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1089\/hgtb.2012.049","article-title":"Quantification of AAV particle titers by infrared fluorescence scanning of coomassie-stained sodium dodecyl sulfate-polyacrylamide gels.","volume":"23","author":"Kohlbrenner","year":"2012","journal-title":"Hum Gene Ther Methods."},{"key":"B57","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/nprot.2006.207","article-title":"Production and characterization of adeno-associated viral vectors.","volume":"1","author":"Grieger","year":"2006","journal-title":"Nat Protoc."},{"key":"B58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/hgtb.2015.013","article-title":"Systematic comparison and validation of quantitative real-time PCR methods for the quantitation of adeno-associated viral products.","volume":"26","author":"Werling","year":"2015","journal-title":"Hum Gene Ther Methods."},{"key":"B59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/hgtb.2011.034","article-title":"Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences.","volume":"23","author":"Aurnhammer","year":"2011","journal-title":"Hum Gene Ther."},{"key":"B60","first-page":"493","article-title":"Simple method of estimating fifty per cent endpoints.","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg."},{"key":"B61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2005.11.010","article-title":"Fcgamma receptors: old friends and new family members.","volume":"24","author":"Nimmerjahn","year":"2006","journal-title":"Immunity."},{"key":"B62","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1080\/21645515.2017.1321722","article-title":"Influenza vaccine effectiveness among high-risk groups: a systematic literature review and meta-analysis of case-control and cohort studies.","volume":"14","author":"Restivo","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00743","article-title":"Influenza virus: a master tactician in innate immune evasion and novel therapeutic interventions.","volume":"9","author":"Hsu","year":"2018","journal-title":"Front Immunol."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00005","article-title":"AAV vectors vaccines against infectious diseases.","volume":"5","author":"Nieto","year":"2014","journal-title":"Front Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coviro.2017.03.002","article-title":"Tackling influenza with broadly neutralizing antibodies.","volume":"24","author":"Corti","year":"2017","journal-title":"Curr Opin Virol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1146\/annurev-immunol-032712-095916","article-title":"Broadly neutralizing antiviral antibodies.","volume":"31","author":"Corti","year":"2013","journal-title":"Annu Rev Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.coi.2015.06.014","article-title":"Engineering humoral immunity as prophylaxis or therapy.","volume":"35","author":"Deal","year":"2015","journal-title":"Curr Opin Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1128\/CVI.00572-14","article-title":"Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus.","volume":"21","author":"Adam","year":"2014","journal-title":"Clin Vaccine Immunol."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines6020027","article-title":"The potential role of Fc-receptor functions in the development of a universal influenza vaccine.","volume":"6","author":"Jegaskanda","year":"2018","journal-title":"Vaccines (Basel)."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2017.1290018","article-title":"Fc or not Fc; that is the question: antibody Fc-receptor interactions are key to universal influenza vaccine design.","volume":"13","author":"Jegaskanda","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006366","article-title":"Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.","volume":"5","author":"Khurana","year":"2013","journal-title":"Sci Transl Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.tim.2016.09.003","article-title":"A structural and mathematical modeling analysis of the likelihood of antibody-dependent enhancement in influenza.","volume":"24","author":"Ramakrishnan","year":"2016","journal-title":"Trends Microbiol."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000258","article-title":"Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada.","volume":"7","author":"Skowronski","year":"2010","journal-title":"PLoS Med."},{"key":"B74","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/mabs.2.3.11782","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.","volume":"2","author":"Brennan","year":"2010","journal-title":"MAbs."},{"key":"B75","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2326-6066.CIR-15-0120","article-title":"Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions.","volume":"3","author":"DiLillo","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1517\/14712598.2016.1165661","article-title":"Half-life extended biotherapeutics.","volume":"16","author":"Kontermann","year":"2016","journal-title":"Expert Opin Biol Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1093\/infdis\/jiz040","article-title":"Predicting the Next Influenza Pandemics.","author":"Neumann","year":"2019","journal-title":"J Infect Dis."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00627\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T11:26:14Z","timestamp":1590751574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00627\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2020.00627"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00627","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"article-number":"627"}}